HAIFA, ISRAEL, March 9, 2015 — Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today that members of its executive and scientific teams will present at two key regenerative medicine conferences in Asia.
In Japan, on March 19, 2015, Zami Aberman, Pluristem’s Chairman and CEO, will deliver a presentation titled “3D Cell Culturing – The Solution for Cell Therapy Quality, Cost, Manufacturing and Efficiency,” at the 14th Congress of the Japanese Society for Regenerative Medicine. The conference will take place on March 19 through 21 in Yokohama. Two scientific posters will also be presented at the conference; one is titled “PLX-R18 in Mitigation of Acute Radiation Syndrome”, and the other is “Intra-muscular Administration of PLX-PAD Cells for the Treatment of Gluteus Medius Muscle Injury Following Total Hip Arthroplasty.”
Recent changes in Japan’s laws governing the approval of new regenerative medicine products indicate that the country now offers a potential rapid track to commercialization for cell therapies. Pluristem is actively exploring partnership opportunities in Japan in order to take full advantage of this new regulatory landscape.
In South Korea, on March 19, 2015, Racheli Ofir, Ph.D., VP Research & Intellectual Property, will chair the session titled “Stem Cell Extraction, Expansion, and Stage Stem Cell Products”, and will give a presentation titled “PLX, Placental-Derived Adherent Stromal Cells – Manufacturing and Properties,” at BIT’s 8th Annual World Congress of Regenerative Medicine & Stem Cell 2015. The conference will take place on March 19 through 21 in Busan.
Pluristem has a joint venture agreement with CHA Biotech (KOSDAQ: 085660), a South Korean company which has licensed the rights to PLX cells for the treatment of intermittent claudication and critical limb ischemia in South Korea. Pluristem’s Phase II global intermittent claudication trial is currently being conducted at sites in the U.S., Germany and Israel in addition to South Korea.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company’s patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company’s proprietary three- dimensional expansion technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem,.com the content of which is not part of this press release.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, forward-looking statements are used in this press release when we discuss exploring potential partnership opportunities in Japan in order to take full advantage of the new regulatory landscape. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem’s reports filed from time to time with the Securities and Exchange Commission.
Contact:
Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109
